Menarini Silicon Biosystems announces PACE trial biomarker analysis results confirming clinical utility of CELLSEARCH CTC enumeration to guide treatment decisions in a specific metastatic breast cancer subtype
The secondary analysis of the PACE trial highlights the value of counting…
Biosplice Therapeutics Announces First Patient Dosed in InvestigatorInitiated Phase 1 Clinical Trial of Cirtuvivint and Olaparib in BRCA/HRD PlatinumResistant Ovarian Cancer
SAN DIEGO, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”),…
InnoCare Announces Approval of Phase II/III Clinical Trial of Novel TYK2 Inhibitor Soficitinib for Chronic Spontaneous Urticaria in China
December 17, 2025 20:48 ET | Source: InnoCare Pharma BEIJING, Dec. 17,…
InnoCare Announces Achievement of Primary Endpoint in Phase IIb Study of Orelabrutinib for SLE and Approval of Phase III Clinical Trial
BEIJING, Dec. 14, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE:…
Accelerating Patient Recruitment and Research Excellence: TrialWire Supports Endpoints Clinical Trials Day NYC 2025
NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- TrialWire®, the industry’s fastest,…
Independent Study Presented at American Society of Hematology (ASH) Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHD
December 11, 2025 18:22 ET | Source: Mesoblast Limited NEW YORK, Dec.…
Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition
93% overall response and 76% complete response rates with median progression-free survival…
American Society of Clinical Oncology (ASCO) announces dates for 2026 ASCO Breakthrough and begins accepting submissions for novel oncology research
Global oncology society calls for abstract submissions for research that is shaping…
Emerald Clinical Appoints Luke Gill as Vice President, Global Head of Oncology, Medical & Scientific Affairs
Accomplished biotech and CRO leader brings 25+ years of global oncology drug…
Quetzal Therapeutics Launches Phase III Clinical Trial of Oral QTX-2101 for Acute Promyelocytic Leukemia (APL)
CHICAGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a biopharmaceutical company…
